Combination Therapy

Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma

Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma

By

Although involved-field radiotherapy (IFRT) has a high level of disease control in patients with follicular lymphoma, relapse frequently occurs; therefore, researchers sought to determine if adding chemotherapy would improve progression-free survival.

Combined Microwave Ablation and Minimally Invasive Open Decompression for the Management of Thoracic Metastasis in Breast Cancer

Combined Microwave Ablation and Minimally Invasive Open Decompression for the Management of Thoracic Metastasis in Breast Cancer

[Cancer Management and Research] An investigation into the efficacy of microwave ablation and minimally invasive open decompression treatment for breast cancer with thoracic metastases.

Ixazomib, Lenalidomide, Dexamethasone Effective But Increases Toxicity in Multiple Myeloma

Ixazomib, Lenalidomide, Dexamethasone Effective But Increases Toxicity in Multiple Myeloma

By

Three-drug regimen twice a week achieved good response and long-term outcomes in patients with newly diagnosed multiple myeloma; however, regimen has higher toxicity than once weekly dose.

Andrographolide Potentiates the Antitumor Effect of Topotecan in Acute Myeloid Leukemia Cells Through an Intrinsic Apoptotic Pathway

Andrographolide Potentiates the Antitumor Effect of Topotecan in Acute Myeloid Leukemia Cells Through an Intrinsic Apoptotic Pathway

[Cancer Management and Research] In this study, researchers explored the potential of andrographolide and topotecan, separately and together, in the in vitro treatment of the U937 acute myeloid leukemic cell line.

No Improvement in OS, DFS With MP + Adjuvant ADT for High-Risk Prostate Cancer

No Improvement in OS, DFS With MP + Adjuvant ADT for High-Risk Prostate Cancer

By

The addition of mitoxantrone and prednisone (MP) to adjuvant androgen-deprivation therapy did not increase survival among patients with high-risk prostate cancer.

Panobinostat vs Placebo: Patient-Reported Outcomes Comparable in Multiple Myeloma

Panobinostat vs Placebo: Patient-Reported Outcomes Comparable in Multiple Myeloma

By

Investigators sought to determine the impact on quality of life for patients with relapsed/refractory multiple myeloma treated with PAN and BTZ+DEX.

Spotlight on Triptorelin in the Treatment of Premenopausal Women with Early-Stage Breast Cancer

Spotlight on Triptorelin in the Treatment of Premenopausal Women with Early-Stage Breast Cancer

[Breast Cancer: Targets and Therapy] Researchers present a review of the LHRH agonist triptorelin and the use of this agent to induce chemical castration in estrogen-sensitive breast cancer tumors in younger women.

Combination Effective as First-Line Therapy in Advanced ER-Positive HER2-Negative Breast Cancer

Combination Effective as First-Line Therapy in Advanced ER-Positive HER2-Negative Breast Cancer

By

In this open label phase 2 BOLERO-4 study, researchers evaluated the effect of everolimus plus endocrine therapy on progression-free survival.

Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma

Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma

By

This treatment-expansion study evaluated the tolerability and safety of the PANEX (panobinostat plus bortezomib with dexamethasone) protocol in heavily treated patients with R/R multiple myeloma.

5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy

5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy

By

A report from a phase 3 study on the 5-year failure-free survival of women with endometrial cancer treated with radiation therapy alone vs chemoradiotherapy plus adjuvant chemotherapy.

Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer

Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer

By

Data presented at the 2018 Gastrointestinal Cancers Symposium compared overall survival with cytoreductive surgery (CRS) alone for patients with gastric cancer and peritoneal carcinomatosis vs treatment with HIPEC plus CRS.

Better Postoperative Outcomes With RAMIE for Esophageal Cancer

Better Postoperative Outcomes With RAMIE for Esophageal Cancer

By

Research presented at the 2018 Gastrointestinal Cancers Symposium described benefits seen with RAMIE vs chemotherapy or chemoradiotherapy plus OTE for esophageal cancer.

Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy

Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy

By

A metabolomics study of the effect of palbociclib/letrozole combination on cancer cells discovered that consumption of foods with certain xenoestrogens has a negative effect on the treatment.

FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC

FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC

By

Combination therapy with lenvatinib and pembrolizumab is granted Breakthrough Therapy Designation for the treatment of advanced or metastatic renal cell carcinoma (RCC).

Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers

Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers

By

The US FDA approved pertuzumab in combination with trastuzumab and chemotherapy for adjuvant treatment of HER2-positive early breast cancer, and converted accelerated to full approval for the regimen as neoadjuvant therapy in certain breast cancers.

Drug Combination Does Not Extend Glioblastoma Survival

Drug Combination Does Not Extend Glioblastoma Survival

Lomustine plus bevacizumab may increase progression-free, but not overall, survival versus lomustine alone in progressive glioblastoma.

Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy

Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy

[OncoTargets and Therapy] This article examines a case of metastatic melanoma in which the patient had an excellent response to apatinib/TMZ combination therapy with progression-free survival for more than one year.

All-Cause Mortality Improved by Advances in Radiotherapy for Hodgkin Lymphoma

All-Cause Mortality Improved by Advances in Radiotherapy for Hodgkin Lymphoma

By

Investigators assessed the impact of advances over time in the treatment of Hodgkin lymphoma on all-cause mortality in patients with Hodgkin lymphoma who received radiotherapy alone or with chemotherapy.

Radiation Prior to Chemotherapy Prolongs Progression-Free Survival in NSCLC

Radiation Prior to Chemotherapy Prolongs Progression-Free Survival in NSCLC

By

Researchers present findings of a phase 2 study that compared PFS when SBRT is administered prior to maintenance chemotherapy in patients with limited metastatic NSCLC vs chemotherapy alone. Data was presented at ASTRO 59th Annual Meeting.

Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination

Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination

By

Overall survival was significantly prolonged in patients with advanced melanoma who were treated with nivolumab plus ipilimumab compared with either drug alone, according to results from the Checkmate 067 study.

Progression-Free Survival in CLL Prolonged With Maintenance Lenalidomide

Progression-Free Survival in CLL Prolonged With Maintenance Lenalidomide

By

Lenalidomide reduced the relative risk of disease progression in a clinical trial of patients with chronic lymphocytic leukemia who did not achieve MRD negative disease state after first-line chemoimmunotherapy.

Adding Thalidomide to Palonosetron, Dexamethasone Reduces CINV

Adding Thalidomide to Palonosetron, Dexamethasone Reduces CINV

By

Delayed CINV was improved significantly in patients receiving highly emetogenic chemotherapy for cancer when thalidomide was added to palonosetron and dexamethasone regimen.

Emerging Combination Therapies for the Management of Multiple Myeloma: The Role of Elotuzumab

Emerging Combination Therapies for the Management of Multiple Myeloma: The Role of Elotuzumab

[Cancer Management and Research] The research examines the various combination strategies for the treatment of multiple myeloma, with a focus on the use of elotuzumab.

Midostaurin Improves Survival in Acute Myeloid Leukemia With FLT3 Mutation

Midostaurin Improves Survival in Acute Myeloid Leukemia With FLT3 Mutation

By

Adding midostaurin, a multitargeted kinase inhibitor, to standard chemotherapy provides significant survival benefit for patients with AML and a FLT3 mutation.

Improved Outcomes in Lung Cancer With Hyperfractionated Chemoradiation Therapy

Improved Outcomes in Lung Cancer With Hyperfractionated Chemoradiation Therapy

By

Twice daily radiation therapy with chemotherapy may improve survival times in patients with some advanced head and neck cancers, a new study confirms.

Pembrolizumab Use With CRT Safe in Locally Advanced HNSCC

Pembrolizumab Use With CRT Safe in Locally Advanced HNSCC

By

Small study also showed that pembrolizumab does not significant impair radiation or chemotherapy dosing.

Survival Increased With First-Line Abiraterone-ADT Combination for Hormone-Naïve Prostate Cancer

Survival Increased With First-Line Abiraterone-ADT Combination for Hormone-Naïve Prostate Cancer

By

Addition of abiraterone to androgen deprivation therapy for patients with hormone-naïve advanced prostate cancer may be a new standard of care.

Continued Enzalutamide Strategy Fails to Benefit mCRPC

Continued Enzalutamide Strategy Fails to Benefit mCRPC

By

Men who had PSA progression on enzalutamide but continued on the drug did not have improved PFS when abiraterone was added to their therapy.

IL-11 Plus Glucocorticoids Safe, Effective for ITP in Adults

IL-11 Plus Glucocorticoids Safe, Effective for ITP in Adults

By

Recent study results demonstrate that recombinant IL-11 with glucocorticoids is a safe and effective treatment for idiopathic thrombocytopenic purpura (ITP) in adults.

Cisplatin Plus Standard-of-Care Regimen Reduced Tumors in Advanced Pancreatic Cancer

Cisplatin Plus Standard-of-Care Regimen Reduced Tumors in Advanced Pancreatic Cancer

By

Cisplatin plus standard-of-care gemcitabine/nab-paclitaxel improved tumor shrinkage in patients with metastatic pancreatic cancer, according to a study by the HonorHealth Research Institute and the Translational Genomics Research Institute.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs